Navigation Links
ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
Date:8/11/2008

une 30, 2008, compared to a net loss of $5.7 million, or $0.06 per share, for the same period in 2007. Included in the net loss for the three-month period ended June 30, 2008 were non-cash, share-based compensation expenses amounting to $0.4 million, compared to $0.6 million for the same period in 2007.

In May 2008, the Company settled its dispute with Theragenex. In consideration of and conditioned upon Theragenex paying the Company $0.6 million, the parties agreed to jointly move to dismiss the underlying arbitration action, and in connection with dismissing the arbitration, agreed to release each other from any and all claims related to their past relationship, including Theragenex's rights under their prior agreement. For the three-month period ended June 30, 2008, the Company recognized $0.5 million in licensing revenue, which represents a portion of the $0.6 million Theragenex settlement payment. The additional $0.1 million was recognized as other income.

Research and development, or R&D, expenses increased by $0.3 million, or 6%, to $4.5 million for the three-month period ended June 30, 2008, from $4.2 million for the same period a year ago. The increase was primarily due to a $1.3 million increase in expenses related to external research-related manufacturing and regulatory and quality assurance activities related to ANX-530 and ANX-514, offset by a $0.8 million decrease in external clinical trial expenses related to ANX-530 and ANX-510, or CoFactor, a decrease of $0.1 million personnel and related costs and a $0.1 million decrease in share-based compensation expense. R&D expenses for the three-month period ended June 30, 2008 included non-cash, share-based compensation expense amounting to $0.1 million, compared to $0.2 million for the same period a year ago.

Selling, general and administrative, or SG&A, expenses increased by $0.6 million, or 31%, to $2.6 million for the three-month period ended June 30, 2008, from $2.0 million for the
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
2. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
3. ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference
4. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference
5. ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference
6. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
7. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
8. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
9. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
10. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
11. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... OR (PRWEB) June 02, 2015 With ... dry in most parts of the United States, people ... conditioned rooms. Despite the obvious benefits of air conditioning, ... effects, including dry eye, dehydration and allergic reactions. Fresh ... Hour™ Power of Water® radio show, will discuss the ...
(Date:6/2/2015)... Bank, New Jersey (PRWEB) June 02, 2015 ... New Jersey’s largest nonprofit provider of home health ... appointment of its President and CEO, Steve Landers, ... America's (VNAA) Board of Directors. , VNAA ... that supports, promotes and advances mission driven, nonprofit ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Mercy Health ... serving Ohio and Kentucky – has devoted the seventh ... videos to skin cancer prevention. One in five Americans ... on Mercy Health’s YouTube channel, a Mercy Health expert ... are the main causes of skin cancer? , ...
(Date:6/2/2015)... 2015 First Choice Emergency Room ... in the United States, named Kenneth Alan Totz, D.O.as ... Road facility. , “We are pleased to announce ... facility,” said Dr. James M. Muzzarelli, Executive Medical Director ... received his undergraduate degree from St. Edwards University in ...
(Date:6/2/2015)... Phoenix, AZ (PRWEB) June 02, 2015 ... Iowa community, has granted $70,000 to the UNMC to support ... NFL Kicker Billy Cundiff, a member of the Colleen’s Dream ... grant was the biggest to date for Colleen’s Dream ... Dr. Wang in Omaha. , “Dr. Wang is a rising ...
Breaking Medicine News(10 mins):Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 2Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 3Health News:Steve Landers, MD, MPH, President and CEO of VNA Health Group Appointed to VNAA Board of Directors 2Health News:Steve Landers, MD, MPH, President and CEO of VNA Health Group Appointed to VNAA Board of Directors 3Health News:Video provides helpful information about skin cancer prevention 2Health News:First Choice Emergency Room Announces Dr. Kenneth Alan Totz as New Medical Director of Houston – Jones Road Facility 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3
... participated in a cardiac-rehab program after a heart attack had ... the same age and sex who had not had a ... that occurred among patients in their study were due to ... involved about 1,800 patients. Nearly 60 percent participated in cardiac ...
... substantial morbidity and mortality and the incidence of MRSA ... to prevent the spread of MRSA including better hand ... the detection and isolation of infected patients. ... were done looking at reducing the spread of MRSA. ...
... reveals women suffering from extremely low body fat whether ... may benefit from treatment with the appetite-and-weight-regulation hormone ... in treating some instances of infertility. ,Leptin is ... stream, where it then travels to the brain and ...
... point to seek mental counseling. Experts say diabetics under ... because of unhealthy habits they implement to deal with ... showed nearly 13 percent of respondents experience psychological symptoms ... under mental distress are more likely than non-stressed diabetics ...
... recent study, a poor oral health diagnosis was a ... such as // high levels of fibrinogen (a clotting ... ,Researchers compared the oral health data of 256 ... characteristics. Results of the study show the strongest predictor ...
... new study shows consuming foods or supplements containing the omega-3 ... to avoid Alzheimer’s disease // even if you carry a ... study researchers first bred mice to carry the gene known ... various environmental factors affecting the symptoms were studied but the ...
Cached Medicine News:
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/56cq5n/motion_simulation ) has ... Market by Type (Hydraulic and Actuator), Degree of ... Application (Automotive, Defense, Entertainment, Healthcare, Mining, R&D, Sports, ... " report to their offering. ... enough for commercial use, and thus its market ...
(Date:6/2/2015)...  Nektar Therapeutics (NASDAQ: NKTR ) and The ... a research collaboration that includes a Phase 1/2 clinical ... preferentially stimulate production of CD8-positive T cells, which are ... which is also known as the Interleukin-2 receptor beta ... to increase proliferation of these effector T cells. 1 ...
(Date:6/2/2015)... , June 2, 2015 Northstar ... first television and multi-media commercial advertisement, which it ... to promote SNORenz®, the company,s top selling product. ... the company,s past success with television advertising. Previous ... but this, more modern version takes an entertainment-oriented ...
Breaking Medicine Technology:Global Motion Simulation Market 2015-2020 - Type, Degree of Freedom, Application, and Regional Analysis 2Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 2Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 3Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 4Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 5Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 6Northstar releases its direct response multi-media ad designed to be used in national television advertising campaigns 2
... Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a ... company will actively participate at the Save A Leg, ... in Orlando tomorrow, October 8. , In addition to exhibiting its ... a workshop entitled " The ...
... ACCESS PHARMACEUTICALS, INC . (OTC ... agreement with iMedicor (OTC Bulletin Board: VMCI) for the North ... rinse for the management of oral mucositis and stomatitis caused ... System application, initial introduction of MuGard to the 216,000 selected ...
Cached Medicine Technology:Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference 2Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference 3Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 2Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 3Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 4
Straight shafts with teeth and 5 mm tying platform. Wide serrated handle with polished finish. Teeth: 0.3 mm. Manufactured in titanium....
Serrated, 10 mm tips angled 90 degrees. Serrated cross action handle with polished finish....
Ergotec Vetriretinal Instrument System. Fine angled tips (3 mm). 20 gauge shaft length with black tip. Overall length from rear rotation knob to tip....
Ergotec Vetriretinal Instrument System. 2 mm pointed black tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
Medicine Products: